Biostar Pharmaceuticals plans to launch its Xin Aoxing Oleanolic Acid Capsules in Beijing and Shanghai in early January 2010. Xin Aoxing is an OTC treatment for hepatitis B that produced 76% of the company’s revenues in Q3. Biostar said it expects the initiative will add $9 million to 2010 revenues, a meaningful addition to the $48 million of revenues that Biostar is on track to report for 2009. More details...

Stock Symbol: (OTCBB: BSPM)